Autoimmunity checkpoints as therapeutic targets in B cell malignancies
Nature Reviews Cancer 18, 103 (2018).
doi:10.1038/nrc.2017.111
Author: Markus Müschen
Targeted therapy of cancer typically focuses on inhibitors (for example, tyrosine kinase inhibitors) that suppress oncogenic signalling below a minimum threshold required for survival and proliferation of cancer cells. B cell acute lymphoblastic leukaemia and B cell lymphomas originate from various stages of development of
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Markus M ΓΌ schen Tags: Perspectives Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer | Cancer & Oncology | Leukemia | Lymphoma